Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 48: 977-978, 2002;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (14)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mair, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mair, J.
Related Collections
Right arrow Proteomics and Protein Markers
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2002;48:977-978.)
© 2002 American Association for Clinical Chemistry, Inc.

Editorial

Role of Cardiac Natriuretic Peptide Testing in Heart Failure

Johannes Mair1a

1 Department of Internal Medicine, Division of Cardiology, University of Innsbruck, A-6020 Innsbruck, Austria

aFax 43-512-504-3379, E-mail Johannes.Mair@uibk.ac.at

The first 300 words of the full text of this article appear below.

The long-predicted natriuretic and endocrine function of the heart was demonstrated more than 20 years ago (1) by the discovery of atrial natriuretic peptide [atrial natriuretic factor, A-type natriuretic peptide (ANP)]. This led to the description of a family of structurally similar but genetically distinct peptides, constituting the natriuretic peptide (NP) family, which contribute to the maintenance of cardiovascular homeostasis. These looped peptides are the naturally occurring antagonists of the renin-angiotensin-aldosterone system and of the sympathetic nervous system. They promote natriuresis and diuresis, act as vasodilators, and exert antimitogenic effects on cardiovascular tissues.

Two members of the NP family, ANP and brain natriuretic peptide [B-type natriuretic peptide (BNP)] are secreted by the hemodynamically stressed heart mainly in response to myocardial stretch induced by volume load. ANP and BNP appear to form a dual, integrated NP system with ANP acting as a rapid-response hormone and BNP as a backup hormone activated only after prolonged ventricular overload. The NP system is activated to its highest degree in ventricular dysfunction and has an important role in maintaining the compensated state of asymptomatic heart failure (HF) and delaying disease progression. The increased plasma ANP and BNP seen in HF patients is not unique: NPs are increased in all patients with edematous disorders, such as renal failure or ascitic liver cirrhosis, that lead to increased atrial tension or central blood volume (2).

The NPs are synthesized as preprohormones. The endocrinologically active C-terminal peptides (ANP and BNP) and their N-terminal prohormone fragments are found in plasma. It is uncertain at present whether the proteolytic cleavage of proBNP to N-terminal proBNP (NT-proBNP) 1–76 and BNP (C-terminal 32 amino acids) occurs at the time of secretion or later in the circulation (3). ProBNP is, however, a substrate of the transmembrane serine protease . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
A. Gegenhuber, J. Struck, W. Poelz, R. Pacher, N. G. Morgenthaler, A. Bergmann, M. Haltmayer, and T. Mueller
Midregional Pro-A-Type Natriuretic Peptide Measurements for Diagnosis of Acute Destabilized Heart Failure in Short-of-Breath Patients: Comparison with B-Type Natriuretic Peptide (BNP) and Amino-Terminal proBNP
Clin. Chem., May 1, 2006; 52(5): 827 - 831.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
A. Lev-Sagie, B. Bar-Oz, L. Salpeter, D. Hochner-Celnikier, I. Arad, and A. Nir
Plasma Concentrations of N-Terminal Pro-B-Type Natriuretic Peptide in Pregnant Women near Labor and during Early Puerperium
Clin. Chem., October 1, 2005; 51(10): 1909 - 1910.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. Rauh and A. Koch
Plasma N-Terminal Pro-B-Type Natriuretic Peptide Concentrations in a Control Population of Infants and Children
Clin. Chem., September 1, 2003; 49(9): 1563 - 1564.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
T. Mueller, A. Gegenhuber, W. Poelz, and M. Haltmayer
Comparison of the Biomedica NT-proBNP Enzyme Immunoassay and the Roche NT-proBNP Chemiluminescence Immunoassay: Implications for the Prediction of Symptomatic and Asymptomatic Structural Heart Disease
Clin. Chem., June 1, 2003; 49(6): 976 - 979.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Association for Clinical Chemistry.